50. Commissioner O of the. FDA Approves First Treatment for COVID-19. FDA. Published October 22, 2020. Accessed February 16, 2021. https://www.fda.gov/news-events/press- announcements/fda-approves-first-treatment-covid-19 51. WHO recommends against the use of remdesivir in COVID-19 patients. Accessed February 16, 2021. https://www.who.int/ news-room/feature-stories/detail/who-recommends-against- the-use-of-remdesivir-in-covid-19-patients 52. Therapeutic Management. COVID-19 Treatment Guidelines. Accessed February 16, 2021. https://www. covid19treatmentguidelines.nih.gov/therapeutic- management/ 53. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255-2273. doi:10.1056/NEJMra2026131 54. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia. medRxiv. Published online September 12, 2020:2020.08.27.20183442. doi:10.1101/2020.08.27.20183442 55. Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;384(1):20-30. doi:10.1056/NEJMoa2030340 56. Tocilizumab reduces deaths in patients hospitalised with COVID-19 — RECOVERY Trial. Accessed February 16, 2021. https://www.recoverytrial.net/news/tocilizumab- reduces-deaths-in-patients-hospitalised-with-covid- 19#:~:text=Tocilizumab%20reduces%20deaths%20in%20 patients%20hospitalised%20with%20COVID%2D19,-11%20 February%202021&text=The%20Randomised%20 Evaluation%20of%20COVID,patients%20with%20severe%20 COVID%2D19. 57. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. Published online December 11, 2020. doi:10.1056/ NEJMoa2031994 58. https://www.fda.gov/media/143823/download. Accessed February 16, 2021. 59. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. Published online July 17, 2020. doi:10.1056/NEJMoa2021436
Hydroxychloroquine with or without Azithromycin in Mild- to-Moderate Covid-19. N Engl J Med. 2020;383(21):2041-2052. doi:10.1056/NEJMoa2019014 37. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020;323(24):2493-2502. doi:10.1001/ jama.2020.8630 38. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-2040. doi:10.1056/ NEJMoa2022926 39. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405-407. doi:10.1016/j.healun.2020.03.012 40. Commissioner O of the. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19. FDA. Published November 13, 2020. Accessed February 16, 2021. https://www.fda.gov/news-events/ press-announcements/coronavirus-covid-19-update-fda- authorizes-monoclonal-antibody-treatment-covid-19 41. An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19. JAMA. Published online December 11, 2020. doi:10.1001/jama.2020.24415 42. ACTIV-3/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N Engl J Med. Published online December 22, 2020. doi:10.1056/NEJMoa2033130 43. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN- COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021;384(3):238-251. doi:10.1056/ NEJMoa2035002 44. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. Published online November 24, 2020. doi:10.1056/NEJMoa2031304 45. Libster R, Pérez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med. Published online January 6, 2021. doi:10.1056/ NEJMoa2033700 46. Commissioner O of the. FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration’s Fight Against Pandemic. FDA. Published August 24, 2020. Accessed February 16, 2021. https://www. fda.gov/news-events/press-announcements/fda-issues- emergency-use-authorization-convalescent-plasma- potential-promising-covid-19-treatment 47. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi:10.1038/s41467-019-13940-6 48. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271. doi:10.1038/ s41422-020-0282-0 49. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813-1826. doi:10.1056/NEJMoa2007764
23
Made with FlippingBook Digital Publishing Software